MML Investors Services LLC increased its position in Agilent Technologies, Inc. (NYSE:A – Get Rating) by 13.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,826 shares of the medical research company’s stock after purchasing an additional 2,511 shares during the quarter. MML Investors Services LLC’s holdings in Agilent Technologies were worth $2,531,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of A. EverSource Wealth Advisors LLC boosted its position in Agilent Technologies by 34.8% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 298 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 77 shares in the last quarter. King Luther Capital Management Corp boosted its position in Agilent Technologies by 0.3% during the 3rd quarter. King Luther Capital Management Corp now owns 24,625 shares of the medical research company’s stock valued at $2,993,000 after acquiring an additional 78 shares in the last quarter. Bell Investment Advisors Inc boosted its position in Agilent Technologies by 2.1% during the 3rd quarter. Bell Investment Advisors Inc now owns 4,153 shares of the medical research company’s stock valued at $505,000 after acquiring an additional 86 shares in the last quarter. Mutual Advisors LLC lifted its holdings in shares of Agilent Technologies by 1.4% during the 3rd quarter. Mutual Advisors LLC now owns 6,638 shares of the medical research company’s stock valued at $807,000 after purchasing an additional 89 shares during the last quarter. Finally, Spinnaker Trust lifted its holdings in shares of Agilent Technologies by 3.1% during the 3rd quarter. Spinnaker Trust now owns 3,139 shares of the medical research company’s stock valued at $382,000 after purchasing an additional 95 shares during the last quarter. Institutional investors own 85.51% of the company’s stock.
Agilent Technologies Price Performance
NYSE:A opened at $141.20 on Monday. Agilent Technologies, Inc. has a 52 week low of $112.52 and a 52 week high of $160.26. The company has a quick ratio of 1.47, a current ratio of 2.03 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $41.78 billion, a PE ratio of 33.86, a price-to-earnings-growth ratio of 2.50 and a beta of 1.04. The stock’s 50-day moving average price is $151.67 and its 200-day moving average price is $142.45.
Agilent Technologies Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 26th. Stockholders of record on Tuesday, April 4th will be given a dividend of $0.225 per share. This represents a $0.90 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date is Monday, April 3rd. Agilent Technologies’s dividend payout ratio (DPR) is presently 21.58%.
Insider Activity
In other news, VP Padraig Mcdonnell sold 672 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $160.00, for a total transaction of $107,520.00. Following the sale, the vice president now directly owns 15,529 shares in the company, valued at approximately $2,484,640. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, VP Padraig Mcdonnell sold 672 shares of Agilent Technologies stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $160.00, for a total value of $107,520.00. Following the sale, the vice president now directly owns 15,529 shares in the company, valued at approximately $2,484,640. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Henrik Ancher-Jensen sold 29,500 shares of Agilent Technologies stock in a transaction dated Wednesday, December 14th. The stock was sold at an average price of $155.78, for a total value of $4,595,510.00. Following the completion of the sale, the senior vice president now owns 70,793 shares in the company, valued at $11,028,133.54. The disclosure for this sale can be found here. Insiders have sold 52,872 shares of company stock worth $8,181,671 in the last ninety days. Company insiders own 0.31% of the company’s stock.
Analysts Set New Price Targets
Several analysts have recently commented on A shares. KeyCorp increased their price objective on Agilent Technologies from $155.00 to $165.00 and gave the company an “overweight” rating in a report on Tuesday, November 22nd. Cowen raised their target price on Agilent Technologies from $160.00 to $168.00 in a research note on Tuesday, November 22nd. SVB Leerink raised their target price on Agilent Technologies from $160.00 to $170.00 and gave the stock an “outperform” rating in a research note on Friday, January 6th. UBS Group raised their target price on Agilent Technologies from $152.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, December 20th. Finally, Wells Fargo & Company upgraded Agilent Technologies from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $150.00 to $170.00 in a research note on Tuesday, January 10th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Agilent Technologies presently has an average rating of “Moderate Buy” and a consensus target price of $162.62.
About Agilent Technologies
Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.
Featured Stories
- Get a free copy of the StockNews.com research report on Agilent Technologies (A)
- MarketBeat Week in Review – 2/20 – 2/24
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
